Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?
Author:
Publisher
Elsevier BV
Subject
Urology,Oncology
Reference56 articles.
1. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer;Mottet;Eur Urol,2011
2. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation;Kreis;Br J Urol,1988
3. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma;Faure;Prostate,1983
4. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide);Kuhn;N Engl J Med,1989
5. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma;Crawford;N Engl J Med,1989
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relugolix: A Review in Advanced Prostate Cancer;Targeted Oncology;2023-01-18
2. Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer;Expert Review of Anticancer Therapy;2022-06-03
3. Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer;Cancers;2022-04-13
4. Follicle‐stimulating hormone promotes growth of human prostate cancer cell line‐derived tumor xenografts;The FASEB Journal;2021-03-16
5. Prostate cancer;Nature Reviews Disease Primers;2021-02-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3